EP3494988B1 - Treatment of antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor - Google Patents
Treatment of antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor Download PDFInfo
- Publication number
- EP3494988B1 EP3494988B1 EP18205998.0A EP18205998A EP3494988B1 EP 3494988 B1 EP3494988 B1 EP 3494988B1 EP 18205998 A EP18205998 A EP 18205998A EP 3494988 B1 EP3494988 B1 EP 3494988B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- inh
- inh protein
- use according
- patients
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229940009550 c1 esterase inhibitor Drugs 0.000 title claims description 121
- 206010052779 Transplant rejections Diseases 0.000 title claims description 99
- 238000011282 treatment Methods 0.000 title claims description 88
- 210000000056 organ Anatomy 0.000 title description 45
- 102000055157 Complement C1 Inhibitor Human genes 0.000 claims description 148
- 108050007539 Plasma protease C1 inhibitor Proteins 0.000 claims description 110
- 238000000034 method Methods 0.000 claims description 51
- 238000002616 plasmapheresis Methods 0.000 claims description 51
- 210000003734 kidney Anatomy 0.000 claims description 49
- 108700040183 Complement C1 Inhibitor Proteins 0.000 claims description 38
- 238000001990 intravenous administration Methods 0.000 claims description 33
- 238000002560 therapeutic procedure Methods 0.000 claims description 32
- 206010063209 Chronic allograft nephropathy Diseases 0.000 claims description 23
- 239000000427 antigen Substances 0.000 claims description 22
- 102000036639 antigens Human genes 0.000 claims description 22
- 108091007433 antigens Proteins 0.000 claims description 22
- 108060003951 Immunoglobulin Proteins 0.000 claims description 21
- 102000018358 immunoglobulin Human genes 0.000 claims description 21
- 102000004169 proteins and genes Human genes 0.000 claims description 20
- 108090000623 proteins and genes Proteins 0.000 claims description 20
- 210000002381 plasma Anatomy 0.000 claims description 18
- 230000008095 long lasting therapeutic effect Effects 0.000 claims description 15
- 230000003907 kidney function Effects 0.000 claims description 13
- 230000001684 chronic effect Effects 0.000 claims description 12
- 229960004641 rituximab Drugs 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 10
- 229960002224 eculizumab Drugs 0.000 claims description 9
- 229960001467 bortezomib Drugs 0.000 claims description 8
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 8
- 230000000781 anti-lymphocytic effect Effects 0.000 claims description 7
- 239000004023 fresh frozen plasma Substances 0.000 claims description 7
- 210000000265 leukocyte Anatomy 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 230000006872 improvement Effects 0.000 claims description 6
- 101001081555 Homo sapiens Plasma protease C1 inhibitor Proteins 0.000 description 62
- 229940088949 cinryze Drugs 0.000 description 60
- 102000044507 human SERPING1 Human genes 0.000 description 60
- 229940068196 placebo Drugs 0.000 description 43
- 239000000902 placebo Substances 0.000 description 43
- 239000000203 mixture Substances 0.000 description 38
- 238000002054 transplantation Methods 0.000 description 28
- 230000000694 effects Effects 0.000 description 23
- 230000001154 acute effect Effects 0.000 description 19
- 230000024203 complement activation Effects 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 15
- 239000013543 active substance Substances 0.000 description 14
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 14
- 238000001802 infusion Methods 0.000 description 13
- 239000008194 pharmaceutical composition Substances 0.000 description 11
- 230000004083 survival effect Effects 0.000 description 11
- 238000001574 biopsy Methods 0.000 description 10
- 230000003247 decreasing effect Effects 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 208000022461 Glomerular disease Diseases 0.000 description 9
- 230000000295 complement effect Effects 0.000 description 9
- 230000004154 complement system Effects 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 210000005084 renal tissue Anatomy 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 230000036470 plasma concentration Effects 0.000 description 8
- 230000000890 antigenic effect Effects 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 229940109239 creatinine Drugs 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 230000009286 beneficial effect Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 208000020832 chronic kidney disease Diseases 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 201000000523 end stage renal failure Diseases 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 206010019860 Hereditary angioedema Diseases 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000011316 allogeneic transplantation Methods 0.000 description 5
- 238000000586 desensitisation Methods 0.000 description 5
- 238000000635 electron micrograph Methods 0.000 description 5
- 238000001493 electron microscopy Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000003285 pharmacodynamic effect Effects 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000015271 coagulation Effects 0.000 description 4
- 238000005345 coagulation Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 208000028208 end stage renal disease Diseases 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 3
- 102000009112 Mannose-Binding Lectin Human genes 0.000 description 3
- 108010087870 Mannose-Binding Lectin Proteins 0.000 description 3
- 241000282520 Papio Species 0.000 description 3
- 206010070834 Sensitisation Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000004761 fibrosis Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 230000002427 irreversible effect Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 229920005862 polyol Polymers 0.000 description 3
- 150000003077 polyols Chemical class 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 230000008313 sensitization Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 238000002689 xenotransplantation Methods 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 102000000989 Complement System Proteins Human genes 0.000 description 2
- 108010069112 Complement System Proteins Proteins 0.000 description 2
- 229940124073 Complement inhibitor Drugs 0.000 description 2
- 108010058861 Fibrin Fibrinogen Degradation Products Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010048748 Graft loss Diseases 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 108010000487 High-Molecular-Weight Kininogen Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000001399 Kallikrein Human genes 0.000 description 2
- 108060005987 Kallikrein Proteins 0.000 description 2
- 102100035792 Kininogen-1 Human genes 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 102000004528 Mannose-Binding Protein-Associated Serine Proteases Human genes 0.000 description 2
- 108010042484 Mannose-Binding Protein-Associated Serine Proteases Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 206010060872 Transplant failure Diseases 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229940088950 c1 esterase inhibitor (human) Drugs 0.000 description 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000000208 fibrin degradation product Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 206010061989 glomerulosclerosis Diseases 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000003001 serine protease inhibitor Substances 0.000 description 2
- 238000010911 splenectomy Methods 0.000 description 2
- 239000008227 sterile water for injection Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- -1 without limitation Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 102000014447 Complement C1q Human genes 0.000 description 1
- 108010078043 Complement C1q Proteins 0.000 description 1
- 108010028778 Complement C4 Proteins 0.000 description 1
- 108010077773 Complement C4a Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 206010023439 Kidney transplant rejection Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 101710132632 Protein C4 Proteins 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 206010049771 Shock haemorrhagic Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 239000012963 UV stabilizer Substances 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 208000037908 antibody-mediated disorder Diseases 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000008721 basement membrane thickening Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000037058 blood plasma level Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000004074 complement inhibitor Substances 0.000 description 1
- 108700005721 conestat alfa Proteins 0.000 description 1
- 229960005020 conestat alfa Drugs 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 229940075234 cytogam Drugs 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 229940069042 gamunex Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 210000000585 glomerular basement membrane Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000008011 inorganic excipient Substances 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000001806 memory b lymphocyte Anatomy 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000008012 organic excipient Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009118 salvage therapy Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- the present disclosure relates generally to methods, compounds and compositions for treating organ transplant rejection in patients and more particularly but not exclusively to methods and pharmaceutical compositions for treating or preventing antibody-mediated rejection in organ transplant patients using a C1-esterase inhibitor.
- DSA donor-specific antibodies
- AMR hyperacute (immediate) antibody-mediated rejection
- sensitized patients face not one, but at least two hurdles to organ donation: (1) blood type compatibility, and (2) sensitization.
- some patients may develop antibodies to their donor organ after transplantation, and such DSA is termed "de novo.” It is now known that a majority of patients that lose their transplant to chronic rejection do so as a result of de novo DSA.
- the treatments available include, for example, rituximab, and plasmapheresis with, or without, intravenous immunoglobulin (IVIg).
- IVIg intravenous immunoglobulin
- Clinical trial entry NCT01147302 of clinicaltrials.gov describes a ViroPharma Phase II study to evaluate the safety, efficacy and pharmacology of human C1 esterase inhibitor in kidney transplant patients with acute antibody-mediated rejection (AMR).
- AMR acute antibody-mediated rejection
- Clinical trial entry NCT01134510 of clinicaltrials.gov describes a CSL-Behring Phase II study of the safety and efficacy of human C1-INH given post-transplant to reduce or prevent complement-dependent, antibody-mediated rejection (AMR) in adult transplant patients with >30% Panel Reactive Antibodies who have undergone desensitization with IVIG + rituximab and/or plasmapheresis.
- AMR antibody-mediated rejection
- Clinical trial entry NCT01035593 of clinicaltrials.gov describes a study to assess the safety, tolerability, and efficacy of recombinant human C1-INH combined with plasmapheresis (PP) and intravenous immune globulin (IVIG) in renal transplant recipients with biopsy-confirmed antibody-mediated rejection (AMR) within 30 days of renal transplantation, compared with PP and IVIG alone.
- PP plasmapheresis
- IVIG intravenous immune globulin
- AMR antibody-mediated rejection
- WO 2013/041677 discloses treatment of cerebral ischemia using a combination of C1-INH and immunoglobulin such as human plasma derived immunoglobulin (IVIg). This document does not mention treatment of AMR of an organ allograft.
- immunoglobulin such as human plasma derived immunoglobulin (IVIg).
- EP 1240904 discloses human C1-INH for use in preventing or delaying hyperacute and/or acute xenotransplant rejection. Allografts are not envisaged.
- the present invention meets the needs in the field by providing methods and compositions for advantageously administering a C1-esterase inhibitor (C1-INH) protein to organ transplant patients who experience or are at risk of experiencing antibody-mediated rejection (AMR) of the transplanted organ.
- C1-INH C1-esterase inhibitor
- the invention provides a C1 esterase inhibitor (C1-INH) protein for use in a method of treating AMR of a kidney allograft in a patient in need thereof, wherein the method comprises intravenous administration of the C1-INH protein at an initial dose of about 5,000 units and six subsequent doses of 2,500 units given every other day for a total of 13 days of administration, wherein the patient is a human leukocyte antigen (HLA) donor-sensitized kidney transplant recipient, and wherein the method results in a long-lasting therapeutic effect.
- HLA human leukocyte antigen
- the method includes early and/or short term duration administration of a therapeutically effective amount of a C1-INH.
- the method includes use of a therapeutically effective amount of the C1-INH that is sufficient to provide long-lasting therapeutic effect.
- the method includes early and/or short term duration administration of a therapeutically effective amount of a C1-INH, wherein the therapeutically effective amount of the C1-INH is sufficient to provide long-lasting therapeutic effect.
- the C1-INH may be a human plasma derived C1-INH, such as Cinryze ® .
- the C1-INH protein is for use in a method of treating AMR of a kidney allograft according to the present invention, wherein the method may include subjecting the patient to plasmapheresis for removing DSA.
- the method may comprise administering intravenous immunoglobulin (IV Ig) and/or fresh frozen plasma.
- packed red blood cells may additionally or alternatively be administered.
- the method may comprise administering an anti-lymphocyte preparation, rituximab, eculizumab, bortezomib, or a combination thereof.
- the method results in a therapeutic effect lasting for at least 6 months after cessation of therapy.
- the therapeutic effect comprises: improvement in renal function, treatment or prevention of chronic or transplant glomerulopathy, or prevention of AMR
- the patient is being or has been treated with one or more other known therapies for treating hyper-acute and/or acute AMR (e.g. plasmapheresis, IV Ig treatment, treatment with one or more of an anti-lymphocyte preparation, rituximab, eculizumab, bortezomib, or a combination thereof, and preferably plasmapheresis and of IVIg treatment).
- therapies for treating hyper-acute and/or acute AMR e.g. plasmapheresis, IV Ig treatment, treatment with one or more of an anti-lymphocyte preparation, rituximab, eculizumab, bortezomib, or a combination thereof, and preferably plasmapheresis and of IVIg treatment.
- a C1-INH and an additional biologically active agent selected from the group consisting of an anti-lymphocyte preparation, rituximab, bortezomib, eculizumab and immunoglobulin (Ig) or a combination thereof as a combined preparation for concurrent or sequential use in a method of treatment of antibody-mediated rejection (AMR) of an organ allograft in a patient in need thereof.
- a preferred additional biologically active agent is immunoglobulin e.g. intravenous immunoglobulin.
- the present disclosure further provides a pharmaceutical composition for treating or delaying the progression of AMR of an organ allograft in a patient in need thereof.
- the pharmaceutical composition may include a C1-INH; an additional biologically active agent, such as an anti-lymphocyte preparation, rituximab, eculizumab, immunoglobulin (Ig), and combinations thereof; and a pharmaceutically acceptable carrier medium.
- kits comprising:(i) a C1-INH; and (ii) an additional biologically active agent selected from the group consisting of an anti-lymphocyte preparation, rituximab, bortezomib, eculizumab, and immunoglobulin (Ig) or a combination thereof, wherein said components (i) and (ii) are packaged for concurrent or sequential administration to a patient, optionally for use in a method of treatment of antibody-mediated rejection (AMR) of an organ allograft in the patient.
- a preferred additional biologically active agent is immunoglobulin e.g. intravenous immunoglobulin.
- the invention provides an efficacious early and/or short term duration therapy for treating AMR in human leukocyte antigen (HLA) donor-sensitized kidney transplant recipients, that provides long-lasting therapeutic effect.
- HLA human leukocyte antigen
- Antibody-mediated rejection is implicated in foiling the transplantation of, for example, heart, lung, liver, pancreas, intestine and kidney allografts in patients. Because there are few experimental and no approved therapies for antibody-mediated rejection (AMR) and outcomes for transplants are strictly monitored by the Centers for Medicare and Medicaid (CMS), patients awaiting organ transplants with DSA are generally prohibited by most transplant centers from receiving donor organs to which they are sensitized. For example, every year several thousand end-stage renal disease (ESRD) patients are prohibited from receiving a potentially life-saving kidney transplant because of a pre-existing antibody (DSA) directed against the donor's cell surface human leukocyte antigens (HLA).
- DSA pre-existing antibody directed against the donor's cell surface human leukocyte antigens
- DSA can cause immediate, or "hyperacute,” antibody-mediated rejection (AMR) resulting in complement-mediated destruction and ultimately, loss of the transplanted organ.
- AMR antibody-mediated rejection
- an agent that is a useful therapy and/or adjunct for desensitized patients in the prevention or treatment of acute AMR may help change paradigms in transplantation, not only permitting access to potentially life-saving transplants, but also decreasing the wait list competition for those without a potential living donor.
- Acute AMR is routinely treated with additional IVIg and plasmapheresis.
- TG transplant glomerulopathy
- IVIg and/or plasmapheresis provided short-lived activity as opposed to long-lasting therapeutic effect because such treatments eventually lose their effectiveness.
- short-lived activity refers to the activity of a treatment type e.g.
- the term “long-lasting therapeutic effect” refers to the activity of a treatment type e.g. against AMR that remains effective from greater than about 3 to 6 months after cessation of therapy (e.g. greater than about 3, 4, 5, 6 months after cessation of therapy, or about 6 months or about 1 year after cessation of therapy).
- TG graft survival
- Some patients with severe acute AMR may require salvage therapy inclusive of rituximab (anti-CD20 antibody) and/or bortezomib (proteasome inhibitor) with or without splenectomy as a last treatment option.
- rituximab anti-CD20 antibody
- bortezomib proteasome inhibitor
- a complement inhibitor would prove a useful therapy and/or adjunct in the treatment of AMR.
- Transplantation of a vascularized allograft involves exposure of the recipient to donor HLA. Processing and presentation of donor HLA determine the recipient's immune response to the transplanted allograft. If soluble donor antigen is presented and recognized by a recipient's CD4 T-lymphocytes, cytokine release (e.g., IL-2) will propagate a cytotoxic T-cell response resulting in acute cellular rejection. B-lymphocyte recognition of donor HLA results in propagation of a memory B-cell response and production of DSA. HLA-DSA complexes stimulate the classical pathway of the complement system resulting in antibody-mediated rejection ( Figure 1 ).
- cytokine release e.g., IL-2
- B-lymphocyte recognition of donor HLA results in propagation of a memory B-cell response and production of DSA.
- HLA-DSA complexes stimulate the classical pathway of the complement system resulting in antibody-mediated rejection ( Figure 1 ).
- DSA can complex with the first component of the classical complement pathway (C1) resulting in activated C1q/r/s and C4, eventually resulting in the formation of membrane attack complexes (C5b-9) and inflammatory cytokine release.
- C1 classical complement pathway
- C5b-9 membrane attack complexes
- cytokines e.g., IL-2, IL-6, and others
- neutrophils and other mediators for example, platelet derived growth factor
- fibrosis irreversible scarring
- the extent and immediacy of the damage is dependent upon whether (and to what extent) the DSA is pre-existing.
- Donor HLA recognition by pre-existing DSA results in immediate (hyperacute) or early (within 1-3 months-accelerated) loss of the transplanted allograft.
- Such pathology may be temporarily alleviated by pre-transplant desensitization protocols (e.g., plasmapheresis and/or IVIg) directed at amelioration of DSA, but providing only short-lived activity in approximately 50% of such patients.
- Terminal complement (C5b-9) proteins (the product of antibody mediated classical complement pathway activation) can elicit production of fibroblast and platelet-derived growth factors from endothelial cells, causing intimal fibrosis, a hallmark of irreversible kidney transplant rejection.
- a preclinical mouse model of sensitized kidney transplantation showed improved graft survival in animals receiving a C5 inhibitor as adjunctive immunosuppression.
- In a study of 16 sensitized human kidney transplant recipients given the anti-C5 monoclonal antibody eculizumab after transplantation only 1/16 (6%) developed acute AMR within the first month after transplant compared with ⁇ 40% of historical controls. However, all had persistent C4d staining and 4/16 (25%) had significant changes consistent with TG/endothelial cell activation. Long term follow up revealed that nearly 50% of these patients had TG after cessation of therapy, not different than the historical control.
- More proximal signalling components of the classical complement cascade may have a greater role in alloimmunity. For instance, mice deficient in complement protein C3 or C4 had impaired T-cell and B-cell alloimmune responses to major histocompatability complex disparate skin grafts, while C5-deficient mice did not exhibit an impaired alloimmune response. Accordingly, there is a greater theoretical efficacy of C1-INH over a C5 inhibiting agent for prevention or treatment of AMR.
- the present invention provides such a therapy, utilizing a C1-INH treatment that provides long-lasting therapeutic effect that meets the needs in the field, as defined in the claims.
- the present invention relates to a C1-INH protein for use in a method of treating antibody-mediated rejection (AMR) of a kidney allograft in a patient in need thereof, wherein the method includes intravenous administration of the C1-INH protein at an initial dose of about 5,000 units and six subsequent doses of 2,500 units given every other day for a total of 13 days of administration, wherein the patient is a human leukocyte antigen (HLA) donor-sensitized kidney transplant recipient, and wherein the method results in a long-lasting therapeutic effect.
- the organ allografts that may be preserved from rejection by the methods disclosed herein include solid organs. Representative examples of solid organs include heart, liver, lung, pancreas, intestine, and kidney.
- the solid organ is kidney, as defined in the claims.
- C1-INH is used for treating AMR resulting from allotransplantation.
- allotransplantation is a type of transplantation which differs substantially from xenotransplantation. Allotransplantation involves transplantation of organs that are from the same species (human-to-human transplant). In contrast, xenotransplantation involves transplantation of organs that are from differing species (e.g., pig-to-human organ transplant).
- pig-to-human organ transplant e.g., pig-to-human organ transplant.
- treatment refers to means for obtaining a desired pharmacologic or physiologic effect, for example.
- the effect may be prophylactic in terms of completely or partially preventing a condition, appearance, disease, or symptom and/or may be therapeutic in terms of a partial or complete cure for a condition and/or adverse effect attributable to a condition or disease.
- C1-INH used in the methods disclosed herein are believed to prevent and/or treat AMR in organ transplants by inhibiting components of the complement system.
- C1-esterase inhibitor C1-INH
- other biologically active agents as also described and defined herein and optionally combined with further treatment steps as also described and defined herein
- treatment and/or prevention of AMR of an organ allograft may be achieved.
- the following effects may be achieved by the present disclosure.
- An improvement or increase in transplant survival in a patient receiving a cross-match positive organ transplant e.g. an organ to which the patient has circulating DSA, which may be identified through pre-transplant cross-match screening (complement-dependent cytotoxicity assay or flow cytometry)). This may be as compared to a patient not being treated in accordance with the invention, or with the same patient before treatment in accordance with the invention.
- C1-INH protein in a method of treating AMR according to the present disclosure can thus alternatively be described as use for improving or increasing transplant survival in a patient receiving a cross-match positive organ (e.g. kidney) transplant.
- a cross-match positive organ e.g. kidney
- C1-INH protein in a method of treating AMR according to the present invention thus may alternatively be expressed as use in treating or preventing chronic glomerulopathy (CG) or transplant glomerulopathy (TG).
- the C1-INH for use in methods according to the invention can result in improvement in renal function of a transplanted kidney when compared to a patient not being treated, or with the same patient before treatment.
- the use of C1-INH protein in a method of treating AMR according to the present invention can be expressed as use for improving the renal function of a transplanted kidney in a patient.
- C1-INH protein in accordance with the present disclosure is believed to prevent and/or treat AMR in organ transplants by inhibiting components of the complement system
- the use of C1-INH in accordance with the present disclosure may also be described as use for treating or preventing tissue destruction tissue resulting from complement activation, e.g. in an allograft patient.
- any reference to C1-INH for use in treating or preventing AMR can be understood to be a reference to C1-INH for use in one or more of the above uses.
- short term duration refers to the duration of drug treatment activities (e.g. period of administration) which may advantageously occur from about 1 to 30 days.
- the short term duration of treatment may be about 10 to 20 days.
- the short term duration of treatment may be about 13 days (e.g. about 11 to 18, 12 to 15 days).
- the term "early” as used herein regarding treatment refers to the timing of treatment that may advantageously occur or be initiated within 1 to 90 days of: (1) organ transplantation, (2) treatment with the standard of care (plasmapheresis and/or IVIg), and/or (3) diagnosis of AMR.
- the treatment may occur or be initiated in less than about 5 to 10 days.
- the treatment may therefore occur or be initiated in less than about 5 to 10 days of (1) organ transplantation, (2) treatment with the standard of care (plasmapheresis and/or IVIg), and/or (3) diagnosis of AMR and may last from about 10 to 30 days.
- C1-INH protein in accordance with the invention may result in a lesser or decreased incidence of CG, in treated patients compared to a patient not being treated in accordance with the invention, or with the same patient before treatment in accordance with the invention. This effect may be observed e.g. by observation of the tissue in appropriate samples, e.g. using histological or EM examination, as referred to in the Examples.
- TG transplant glomerulopathy
- CG chronic glomerulopathy
- the patient is in general an organ transplant patient (e.g. a kidney transplant or allograft patient, e.g. who has received or who is to receive a transplant or allograft).
- the patient may be experiencing or may be at risk from AMR.
- the AMR may arise as a result of pre-existing donor-specific antibodies (DSA), e.g. donor-specific antibodies present before the transplant or de novo DSA.
- DSA donor-specific antibodies
- the patient may be being treated with one or more other therapies for AMR (e.g. intravenous immunoglobulin (IVIg), or a combination of plasmapheresis and IVIg, or plasmapheresis) or may have been treated with one or more other therapies for AMR.
- the treatment is preferably for decreasing DSA titers where the antibodies are directed against the HLA of the organ to be transplanted or which has been transplanted.
- DSA donor-specific antibodies
- the patient may be an end-stage renal disease (ESRD) patient.
- ESRD patient may have a pre-existing antibody (DSA) directed against the donor's cell surface human leukocyte antigens (HLA) (e.g. a sensitized ESRD patients).
- DSA pre-existing antibody directed against the donor's cell surface human leukocyte antigens (HLA) (e.g. a sensitized ESRD patients).
- HLA human leukocyte antigens
- the patient may optionally have been subject to treatment to desensitize them or may be subject to such treatment at the time of the treatment of the invention (e.g. a treatment to decrease DSA titers, e.g. intravenous immunoglobulin (IVIg), or a combination of plasmapheresis and IVIg, or plasmapheresis).
- the patient may therefore have been subject to a treatment, or may be subject to such treatment to decrease DSA titers, e.g. subjected to intravenous immunoglobulin (IVIg) or a combination of plasmapheresis, or plasmapheresis).
- the desensitising treatment is preferably a desensitising treatment for decreasing DSA titers where the antibodies are directed against the HLA of the organ to be transplanted or which has been transplanted.
- IVIg intravenous immunoglobulin
- plasmapheresis a combination of plasmapheresis, or plasmapheresis
- this is preferably within the preceding week, 2 weeks, 4 weeks, 1 month, 6 weeks, 2 months, or 6 months, or within the preceding year, e.g. of initiating treatment of the invention.
- C1 esterase inhibitor is an endogenous plasma protein in the family of serine protease inhibitors (SERPINs) and has broad inhibitor activity in the complement, contact, and coagulation pathways.
- C1-INH inhibits the classical pathway of the complement system by binding C1r and C1s and inhibits the mannose-binding lectin-associated serine proteases in the lectin pathway.
- the C1-INH of the present invention may be a plasma derived C1-INH or may be recombinantly produced C1-INH, and in both cases may be isolated.
- the C1-INH of the invention is a plasma derived C1-INH.
- the C1-INH of the invention is nanofiltered.
- Unit refers to the measure of protein (C1 INH) material, that is normalized to physiologic levels in human (i.e. 1 U/mL of serum is physiologic). In the alternative, one (1) Unit denotes 240 ⁇ g of protein material unless otherwise indicated.
- a nanofiltered plasma derived C1-INH (Cinryze ® ; Viropharma) is FDA approved for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a disease characterized by constitutional deficiency or dysfunction of endogenous C1 esterase inhibitor.
- HAE hereditary angioedema
- Cinryze ® is known to be well tolerated in humans via the experience in patients with HAE studied in randomized trials as well as in an extension trial. The most frequent adverse events reported at the doses used for HAE were headaches and nasopharyngitis.
- C1-INH is an ideal therapeutic, either alone or as part of a combination therapy or composition, for diseases that implicate, for example, the classical complement pathway (e.g., antibody-mediated diseases) and of the lectin pathway (e.g., ischemia reperfusion injury), and is preferred in the invention.
- the classical complement pathway e.g., antibody-mediated diseases
- lectin pathway e.g., ischemia reperfusion injury
- conestat alfa the recombinant analogue of the human C1 esterase inhibitor (rhC1-INH) (which is produced by recombinant DNA technology in the milk of transgenic rabbits).
- effective amount refers to the quantity of a compound or composition that achieves a beneficial clinical outcome when the compound or composition is administered to a patient.
- a composition of the invention is administered to a patient with, for example, AMR, a "beneficial clinical outcome" includes improved renal function and/or an increase in the longevity of the patient's allograft (e.g., transplanted kidney).
- renal function is defined with respect to the ability of a patient's kidneys to clear creatinine from the body.
- a patient demonstrating increased renal function would present with certain creatinine clearance ability (mL/min) (i.e., baseline) and such creatinine clearance ability or renal function would increase in magnitude from the baseline during treatment and after treatment.
- Any increases may for example be statistically significant, and include increases of at least 10%, 20%, 50%, 100%. Any comparisons can be made with a patient not being treated in accordance with the invention, or with the same patient before treatment in accordance with the invention.
- Beneficial outcome can also be assessed e.g. by determining the presence or extent of CG and/or TG (a reduction in the presence or extent of CG and/or TG being a beneficial outcome). To the extent that this can be quantified, any such decreases may for example be statistically significant, and include decreases of at least 10%, 20%, 50%, 100%. Any comparisons can be made with a patient not being treated in accordance with the invention, or with the same patient before treatment in accordance with the invention.
- the beneficial clinical outcome may be achieved and assessed or determined at any time point.
- the beneficial clinical outcome may be achieved and assessed or determined greater than about 3 to 6 months after cessation of therapy (e.g. greater than about 3, 4, 5, 6 months after cessation of therapy, or about 6 months or about 1 year after cessation of therapy).
- the kidney may show (i) increased and/or sustained function, and/or (ii) reduced presence and/or extent of CG and/or TG, at about 3 to 6 months after cessation of therapy (e.g. greater than about 3, 4, 5, 6 months after cessation of therapy, or about 6 months or about 1 year after cessation of therapy). Any comparisons can be made with a patient not being treated in accordance with the invention, or with the same patient before treatment in accordance with the invention.
- isolated refers to material removed from its original environment (e.g., the natural environment if it is naturally occurring).
- a naturally-occurring polypeptide i.e., protein
- a naturally-occurring polypeptide i.e., protein
- the same polypeptide separated from some or all of the coexisting materials in the natural system, is isolated.
- proteins described herein can be naturally purified products, or chemically synthesized products, or recombinant products from prokaryotic or eukaryotic hosts (e.g., bacteria, yeast, higher plant, insect, or mammalian cell). Such proteins can be glycosylated or non-glycosylated according to the different hosts used.
- the recombinant C1-INH (rC1-INH) proteins can be expressed or produced by conventional recombinant DNA technology, using a polynucleotide sequence specific to C1-INH as known in the art.
- recombinant procedure comprises the following steps:
- compositions, preparations and kits may comprise a C1-INH and another biologically active agent as described herein for concurrent or sequential use.
- Concurrent administration may include administration of two or more agents, compositions or components of the invention (e.g. the components of the compositions and kits of the invention) simultaneously and/or within 12 hours of each other, within 6 hours, within 3 hours, within 2 hours or within 1 hour of each other, typically within the same visit to a clinical centre.
- Sequential administration may include administration of two or more agents, compositions or components of the invention (e.g. the components of the compositions of the invention) within 1 month, within 2 weeks (e.g. within 14 ⁇ 2 days), within a week, within 3 days, within 2 days, or within 24 hours of each other.
- compositions may be administered by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal, and intestinal mucosa, etc.). Administration may further be systemic or local. And administration can be acute or chronic (e.g., daily, weekly, monthly, etc.).
- the intravenous route is exemplified and preferred.
- the orally administered dosage unit may be in the form of tablets, caplets, dragees, pills, semisolids, soft or hard gelatin capsules, aqueous or oily solutions, emulsions, suspensions or syrups.
- Representative examples of dosage forms for parenteral administration include injectable solutions or suspensions, suppositories, powder formulations, such as microcrystals or aerosol spray.
- the composition may also be incorporated into a conventional transdermal delivery system.
- Methods disclosed herein refer to administering compounds, including C1-INH. Such compounds may be present in a composition, e.g. a pharmaceutical composition.
- the disclosed compositions may be administered at a dose in range from about 10 Units (U) of composition or compound per kg body weight (U/kg) to about 250 U/kg, e.g. per day or, preferably, every other day of treatment.
- a dose of from about 25 to 150 U/kg, and preferably from about 50 to 125 U/kg per day or, preferably, every other day of treatment should be effective to produce the desired result.
- a suitable dose for IV administration would include an initial intravenous infusion of about 100 U/kg on day 1, followed by about 50 U/kg e.g. 50 U/kg on day 3 (and optionally about 50 U/kg e.g. 50 U/kg in subsequent treatments, e.g.
- the compounds used in the disclosed method may typically be administered from 1-4 times a day or every other day, so as to deliver the above-mentioned dosage regimen.
- dosage of the compositions of the invention may be expressed as an amount of compound or composition divided equally or unequally over a course of treatment.
- a course of treatment may last from about 1 to 30 days (e.g. 10 to 20 days or, preferably, 13 days (e.g. about 11 to 18, 12 to 15 days)) and about 1,000 to 25,000 units (U) of composition may be administered in divided doses over that course of treatment.
- about 5,000 to 20,000 Units of composition may be administered by IV in divided doses over 10 to 20 days or, preferably, 13 days (or about 6,000-25,000U, 8,000 to 22,000U, 10,000-20,000U, 12,000-18000U, 14,000-16,000U 20,000U over e.g.
- the C1-INH protein of the invention is for use in a method of treating AMR of a kidney allograft in a patient in need thereof, wherein the method comprises intravenous administration of the C1-INH protein at an initial dose of about 5,000 units and six subsequent doses of 2,500 units given every other day for a total of 13 days of administration, as defined in the claims.
- the dosages of the compositions is defined as an amount of compound or composition that is sufficient to achieve an amount of compound or composition that is at least 100% above normal values, e.g. determined 1 hour post administration. In some embodiments the level of at least 100% above normal values is maintained over the course of treatment e.g. about 1 to 30 days (e.g 10 to 20 days or, preferably, 13 days (e.g. about 11 to 18, 12 to 15 days)).
- the exact regimen for administration of the compounds described herein will necessarily be dependent on the needs of the individual subject being treated, the type of treatment administered and the judgment of the attending medical specialist.
- the terms "subject” and “patient” includes both humans and animals.
- the dosage actually administered will depend upon the condition being treated, the age, health and weight of the recipient, the type of concurrent treatment, if any, and the frequency of treatment.
- the effective dosage amount may be determined by one skilled in the art on the basis of routine empirical activity testing to measure the bioactivity of the compound(s) in a bioassay, and thus establish the appropriate dosage to be administered.
- the C1-INH protein for use in a method of treating AMR of a kidney allograft according to the present invention may be administered as an adjunct to plasmapheresis therapy and/or IVIg.
- a composition including C1-INH e.g., Cinryze ®
- a composition including C1-INH may be administered to a patient as 20,000 units provided in divided doses (each dose not exceeding about 100 U/kg) over 10 to 20 days as an adjunct to plasmapheresis and/or IVIg.
- Such treatment may reduce the rate of chronic AMR at 3-6 months after cessation of therapy.
- C1-INH protein used in practicing the invention may be delivered as a pharmaceutical composition that includes a pharmaceutically acceptable carrier medium.
- a pharmaceutical composition for treating or delaying the progression of antibody-mediated rejection (AMR) of an organ allograft in a patient in need thereof the composition including a C1-esterase inhibitor (C1-INH); an additional biologically active agent, such as an anti-lymphocyte preparation, rituximab, bortezomib, eculizumab, immunoglobulin (Ig), or a combination thereof; and a pharmaceutically acceptable carrier medium.
- the expression "pharmaceutically acceptable carrier medium” includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface agent agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants, fillers and the like as suited for the particular dosage form desired.
- any conventional pharmaceutical carrier medium is incompatible with the compositions described herein, such as by producing an undesirable biological effect or otherwise interacting in an deleterious manner with any other component(s) of a formulation comprising the active agent(s), its use is contemplated to be within the scope of this invention.
- compositions disclosed herein may be mixed with pharmaceutically inert, inorganic or organic excipients, such as lactose, sucrose, glucose, gelatine, malt, silica gel, starch or derivatives thereof, talc, stearic acid or its salts, dried skim milk, vegetable, petroleum, animal or synthetic oils, wax, fat, polyols, and the like.
- pharmaceutically inert, inorganic or organic excipients such as lactose, sucrose, glucose, gelatine, malt, silica gel, starch or derivatives thereof, talc, stearic acid or its salts, dried skim milk, vegetable, petroleum, animal or synthetic oils, wax, fat, polyols, and the like.
- Liquid solutions, emulsions or suspensions or syrups one may use excipients such as water, alcohols, aqueous saline, aqueous dextrose, polyols, glycerine, lipids, phospholipids, cyclodextrins, vegetable, petroleum, animal or synthetic oils.
- Suppositories may include excipients, such as vegetable, petroleum, animal or synthetic oils, wax, fat and polyols.
- Aerosol formulations may include compressed gases suitable for this purpose, such as oxygen, nitrogen and carbon dioxide.
- composition or formulation disclosed herein may also contain one or more additives including, without limitation, preservatives, stabilizers, e.g., UV stabilizers, emulsifiers, sweeteners, salts to adjust the osmotic pressure, buffers, coating materials and antioxidants.
- additives including, without limitation, preservatives, stabilizers, e.g., UV stabilizers, emulsifiers, sweeteners, salts to adjust the osmotic pressure, buffers, coating materials and antioxidants.
- the present disclosure further provides controlled-release, sustained-release, or extended-release therapeutic dosage forms for the pharmaceutical composition, in which the composition is incorporated into a delivery system.
- This dosage form controls release of the active agent(s) in such a manner that an effective concentration of the active agent(s) in the bloodstream can be maintained over an extended period of time, with the concentration in the blood remaining relatively constant, to improve therapeutic results and/or minimize side effects.
- a controlled-release system would provide minimum peak to trough fluctuations in blood plasma levels of the active agent of the invention.
- compositions that comprise C1-INH, or C1-INH in combination with a biologically active agent, such as immunoglobulin (Ig), rituximab, bortezomib and/or eculizumab, for example.
- a biologically active agent such as immunoglobulin (Ig), rituximab, bortezomib and/or eculizumab, for example.
- such compositions may, for example, be encapsulated in liposomes, microparticles, and microcapsules, for example.
- the methods disclosed herein will normally include medical follow-up to determine the therapeutic or prophylactic effect brought about in the patient undergoing treatment with the compound(s) and/or composition(s) described herein.
- Cinryze ® C1 esterase inhibitor [human]
- the objectives of the study were: (a) to assess the safety and tolerability of Cinryze ® in kidney transplant patients with acute antibody-mediated rejection (AMR); (b) to assess the effect of Cinryze ® for the treatment of acute AMR in kidney transplant patients; and (c) to examine the pharmacokinetics and pharmacodynamics of Cinryze ® in kidney transplant patients with acute AMR.
- Cinryze ® was supplied as a lyophilized powder of 500 U (C1-INH)/vial. Cinryze ® product and sterile water for injection approved for commercial distribution were utilized. Each vial of Cinryze ® was reconstituted with sterile water for injection(s). Placebo consisted of 0.9% sodium chloride for infusion.
- post-treatment evaluations were performed on Day 20 and Day 90.
- the end of the study was defined as the date that the last subject completed the Day 90 evaluation.
- Complement and C1-INH levels were assessed at specified time points up to Day 20 for PK/PD determinations.
- an optional PK/PD sampling time point was included for Day 25.
- Cinryze ® has a half-life of about 60 hours in HAE patients, subsequent doses of 2500 U given every other day may maintain adequate functional C1-INH levels throughout the dosing period. Therefore, subjects randomized to the Cinryze ® group in this study will receive a loading dose of 5000 U (not to exceed 100 U/kg) followed by 2500 U (not to exceed 50 U/kg) every other day for a total of 7 doses.
- This regimen balances the apparent dose-dependent nature of inhibiting complement activation elicited by antigen-antibody complexes, while minimizing the potential risk of coagulation observed in preclinical and clinical studies with other C1-INH compounds at doses ⁇ 200 U/kg.
- a total of 7 doses of Cinryze ® or placebo (0.9% sodium chloride solution for infusion) were administered as follows: (a) an initial dose of 5000 U of Cinryze ® (not to exceed 100 U/kg) or placebo as a single IV infusion on Day 1; and then (b) 2500 U of Cinryze ® (not to exceed 50 U/kg) or placebo IV every other day for 2 weeks (Days 3, 5, 7, 9, 11, and 13).
- Each dose of study drug was to be administered IV at a rate of approximately 1 mL (corresponding to 100 U of Cinryze ® ) per minute as tolerated.
- the duration of the 5000 U (50 mL) infusion on Day 1 was to be approximately 50 minutes and the duration of the 2500 U (25 mL) infusions on Days 3, 5, 7, 9, 11, and 13 was to be approximately 25 minutes.
- the 'start' and 'stop' times and dates of each study drug infusion was to be recorded.
- Plasmapheresis, fresh frozen plasma, and IVIg Plasmapheresis therapy was to be performed for the qualifying episode of AMR. Regardless of plasmapheresis schedule, study drug was to be administered on Days 1, 3, 5, 7, 9, 11, and 13. Moreover, as demonstrated in Figure 3 , certain patients were provided with, as necessary, the standard of care that included plasmapheresis, plasma replacement in the form of fresh frozen plasma (FFP), blood, and/or IVIg (e.g., cytogam, gamunex, etc.).
- FFP fresh frozen plasma
- IVIg e.g., cytogam, gamunex, etc.
- complement C1q, C4, and C4a levels were evaluated. Blood samples for the determination of plasma concentrations of C1-INH functional and antigenic and complement components C1q, C4, and C4a were collected (Table 1). If plasmapheresis was to be performed on a dosing day, blood samples for PK/PD testing was to be obtained before plasmapheresis, as well as prior to study drug administration (i.e., post-plasmapheresis), and at time points relative to the start of the study drug infusion. Table 1.
- Cinryze ® patients exhibited increased C1-INH functional and classical complement system inhibition where baseline levels were subtracted for calculation of the mean to demonstrate the overall effect of study drug therapy in each cohort.
- Cinryze ® patients demonstrated increased levels (above baseline entry levels) of both C1-INH antigenic and functional in plasma, indicating a greater concentration of active and total C1-INH beyond the levels which patients began their study dosing.
- Cinryze ® patients exhibited evidence of systemic inhibition of the complement system in the fluid phase. Patients treated with Cinryze ® exhibited an increased plasma concentration (corrected for baseline entry levels) of Clq and C4, which are classical complement pathway proteins that would show a decreased concentration in plasma if the classical complement pathway were uninhibited. However, since the concentration of Clq and C4 is increased, this indicates some level of systemic inhibition.
- CG Chronic glomerulopathy
- Figure 6A represents normal renal tissue at six months.
- Figure 6B demonstrates CG as a result of ongoing AMR. In those patients treated with placebo, 3 of 7 displayed CG, whereas, in those patients treated with Cinryze ® , only 1 of 7 displayed CG.
- EM electron microscopy
- the present invention encompasses methods of using C1-INH protein (e.g., Cinryze ® ) as a therapy and/or add-on therapy to standard care (i.e., plasmapheresis and IVIg: both of which address donor specific antibodies) for treating AMR in kidney allograft transplant patients, as defined in the claims.
- C1-INH protein e.g., Cinryze ®
- standard care i.e., plasmapheresis and IVIg: both of which address donor specific antibodies
- the dosing regimen provided unexpected benefits. It is currently unknown if kidney transplant patients could ever achieve a level of C1-INH functional protein sufficient enough to effectively reduce complement activation systemically or within the transplant allograft. Indeed, the dosage of 20,000 units given in divided doses over 13 days was selected. This dose was satisfactory, not only clinically, but also in the increase of serum C1-INH functional levels above baseline.
- kidney transplant patients are treated with 20,000 Units of Cinryze ® over 13 days: (a) the dosage regimen was well tolerated by the kidney transplant patients; (b) such patients maintained supraphysiologic levels of C1-INH as a result of Cinryze ® treatment; (c) such patients demonstrated early improvement in renal function; and (d) such patients demonstrated less glomerulopathy at 6 months with respect to placebo. Therefore, the treatment methodology tested provided long-lasting therapeutic effect against AMR as compared to the treatments currently in the field.
- compositions and methods described herein that embody the present invention can, in alternate embodiments, be more specifically defined by any of the transitional terms “comprising,” “consisting essentially of,” and “consisting of.”
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22188379.6A EP4162947A1 (en) | 2013-11-22 | 2014-11-21 | Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361907550P | 2013-11-22 | 2013-11-22 | |
US201462029086P | 2014-07-25 | 2014-07-25 | |
PCT/US2014/066784 WO2015077543A1 (en) | 2013-11-22 | 2014-11-21 | Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor |
EP14809567.2A EP3071219B1 (en) | 2013-11-22 | 2014-11-21 | Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP14809567.2A Division EP3071219B1 (en) | 2013-11-22 | 2014-11-21 | Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP22188379.6A Division EP4162947A1 (en) | 2013-11-22 | 2014-11-21 | Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3494988A1 EP3494988A1 (en) | 2019-06-12 |
EP3494988B1 true EP3494988B1 (en) | 2022-08-03 |
Family
ID=52016153
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP14809567.2A Active EP3071219B1 (en) | 2013-11-22 | 2014-11-21 | Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor |
EP18205998.0A Active EP3494988B1 (en) | 2013-11-22 | 2014-11-21 | Treatment of antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor |
EP22188379.6A Pending EP4162947A1 (en) | 2013-11-22 | 2014-11-21 | Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP14809567.2A Active EP3071219B1 (en) | 2013-11-22 | 2014-11-21 | Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP22188379.6A Pending EP4162947A1 (en) | 2013-11-22 | 2014-11-21 | Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor |
Country Status (23)
Country | Link |
---|---|
US (3) | US9895428B2 (hu) |
EP (3) | EP3071219B1 (hu) |
JP (5) | JP6431912B2 (hu) |
KR (2) | KR102312817B1 (hu) |
CN (2) | CN105744949A (hu) |
AU (2) | AU2014352846B2 (hu) |
BR (1) | BR112016011499A2 (hu) |
CA (1) | CA2930964A1 (hu) |
CY (1) | CY1121298T1 (hu) |
DK (1) | DK3071219T3 (hu) |
ES (1) | ES2708655T3 (hu) |
HR (1) | HRP20190184T1 (hu) |
HU (1) | HUE041809T2 (hu) |
LT (1) | LT3071219T (hu) |
ME (1) | ME03318B (hu) |
MX (2) | MX2016006656A (hu) |
NZ (2) | NZ759187A (hu) |
PL (1) | PL3071219T3 (hu) |
PT (1) | PT3071219T (hu) |
RS (1) | RS58343B1 (hu) |
SG (1) | SG10201804326SA (hu) |
SI (1) | SI3071219T1 (hu) |
WO (1) | WO2015077543A1 (hu) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT3071219T (pt) | 2013-11-22 | 2019-02-06 | Shire Viropharma Inc | Métodos de tratamento da rejeição mediada por anticorpos em pacientes transplantados de órgãos com inibidor da c1-esterase |
AU2018334213A1 (en) * | 2017-09-15 | 2020-03-26 | Cedars-Sinai Medical Center | Methods for improving organ function in organ transplant patients |
WO2019166572A1 (en) * | 2018-02-28 | 2019-09-06 | Pharming Intellectual Property B.V. | Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor |
AU2019404553A1 (en) * | 2018-12-20 | 2021-06-24 | Cedars-Sinai Medical Center | Clazakizumab in the treatment of chronic antibody-mediated rejection of organ transplant |
JP2022543456A (ja) * | 2019-08-08 | 2022-10-12 | シーダーズ-サイナイ メディカル センター | 臓器機能を改善する方法 |
EP3895726A1 (en) | 2020-04-17 | 2021-10-20 | Pharming Intellectual Property BV | Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress |
KR20230110563A (ko) | 2020-11-20 | 2023-07-24 | 체에스엘 베링 게엠베하 | 항체 매개 거부 반응의 치료 방법 |
CN113035369B (zh) * | 2021-03-10 | 2021-12-03 | 浙江大学 | 一种肾移植抗感染药物剂量预测模型的构建方法 |
CA3225079A1 (en) | 2021-07-09 | 2023-01-12 | Bruno Giannetti | Using c1 esterase inhibitor to treat viral infection-related symptoms |
WO2024152030A1 (en) * | 2023-01-13 | 2024-07-18 | The Uab Research Foundation | Crossmatching for porcine xenotransplantation |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU540709B2 (en) * | 1982-04-12 | 1984-11-29 | Mattel, Inc. | Hair braiding |
JP4212278B2 (ja) * | 2001-03-01 | 2009-01-21 | 日本たばこ産業株式会社 | 移植片拒絶反応抑制剤 |
DE10112617A1 (de) | 2001-03-14 | 2002-10-02 | Aventis Behring Gmbh | Verwendung eines C1-Esterase-Inhibitors zur Verhinderung oder Verzögerung der Abstoßung von Xenotransplantaten in Säugetieren |
WO2006133403A2 (en) | 2005-06-07 | 2006-12-14 | The Regents Of The University Of Colorado | Inhibitors of serine protease activity and their use in methods and compositions for treatment of graft rejection and promotion of graft survival |
RS53864B1 (en) * | 2006-03-02 | 2015-08-31 | Alexion Pharmaceuticals, Inc. | EXTENDING ALOGRAPHIC SURVIVAL BY INHIBITING COMPLEMENT ACTIVITIES |
CN104010656B (zh) * | 2011-09-24 | 2016-02-24 | 德国杰特贝林生物制品有限公司 | 使用免疫球蛋白和c1-抑制剂的联合疗法 |
DK2964255T3 (da) * | 2013-03-08 | 2021-02-08 | Csl Behring Gmbh | Behandling og forebyggelse af fjerntliggende iskæmi-reperfusionsskade (IRI) |
DK3290046T3 (en) * | 2013-03-15 | 2019-03-18 | Shire Viropharma Inc | C1-INH COMPOSITIONS AND PROCEDURES FOR PREVENTION AND TREATMENT OF DISEASES ASSOCIATED WITH C1-ESTERASE INHIBITOR LACK |
PT3071219T (pt) | 2013-11-22 | 2019-02-06 | Shire Viropharma Inc | Métodos de tratamento da rejeição mediada por anticorpos em pacientes transplantados de órgãos com inibidor da c1-esterase |
-
2014
- 2014-11-21 PT PT14809567T patent/PT3071219T/pt unknown
- 2014-11-21 ME MEP-2019-31A patent/ME03318B/me unknown
- 2014-11-21 NZ NZ759187A patent/NZ759187A/en unknown
- 2014-11-21 SG SG10201804326SA patent/SG10201804326SA/en unknown
- 2014-11-21 NZ NZ719724A patent/NZ719724A/en unknown
- 2014-11-21 BR BR112016011499-0A patent/BR112016011499A2/pt not_active Application Discontinuation
- 2014-11-21 WO PCT/US2014/066784 patent/WO2015077543A1/en active Application Filing
- 2014-11-21 DK DK14809567.2T patent/DK3071219T3/en active
- 2014-11-21 RS RS20190148A patent/RS58343B1/sr unknown
- 2014-11-21 EP EP14809567.2A patent/EP3071219B1/en active Active
- 2014-11-21 CA CA2930964A patent/CA2930964A1/en not_active Abandoned
- 2014-11-21 LT LTEP14809567.2T patent/LT3071219T/lt unknown
- 2014-11-21 EP EP18205998.0A patent/EP3494988B1/en active Active
- 2014-11-21 AU AU2014352846A patent/AU2014352846B2/en active Active
- 2014-11-21 US US14/550,075 patent/US9895428B2/en active Active
- 2014-11-21 CN CN201480063697.5A patent/CN105744949A/zh active Pending
- 2014-11-21 MX MX2016006656A patent/MX2016006656A/es unknown
- 2014-11-21 PL PL14809567T patent/PL3071219T3/pl unknown
- 2014-11-21 HU HUE14809567A patent/HUE041809T2/hu unknown
- 2014-11-21 ES ES14809567T patent/ES2708655T3/es active Active
- 2014-11-21 JP JP2016532586A patent/JP6431912B2/ja active Active
- 2014-11-21 KR KR1020167013463A patent/KR102312817B1/ko active IP Right Grant
- 2014-11-21 EP EP22188379.6A patent/EP4162947A1/en active Pending
- 2014-11-21 SI SI201431066T patent/SI3071219T1/sl unknown
- 2014-11-21 CN CN202010018792.0A patent/CN111388655A/zh active Pending
- 2014-11-21 KR KR1020217032180A patent/KR102384814B1/ko active IP Right Grant
-
2016
- 2016-05-20 MX MX2021000332A patent/MX2021000332A/es unknown
-
2017
- 2017-12-18 US US15/844,850 patent/US20180104319A1/en not_active Abandoned
-
2018
- 2018-10-15 JP JP2018194167A patent/JP6620206B2/ja active Active
- 2018-11-15 JP JP2018214342A patent/JP2019023233A/ja not_active Withdrawn
-
2019
- 2019-01-29 CY CY20191100119T patent/CY1121298T1/el unknown
- 2019-01-29 HR HRP20190184TT patent/HRP20190184T1/hr unknown
-
2020
- 2020-01-02 AU AU2020200015A patent/AU2020200015B2/en active Active
- 2020-08-03 US US16/983,998 patent/US20200360495A1/en not_active Abandoned
-
2021
- 2021-01-29 JP JP2021012833A patent/JP2021063141A/ja not_active Withdrawn
-
2022
- 2022-10-11 JP JP2022163044A patent/JP2022179637A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2020200015B2 (en) | Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor | |
JP5873047B2 (ja) | 溶血性疾患の処置方法 | |
US7820617B2 (en) | Methods of selecting immunoregulator peptides obtained from gonadotropins | |
US7402322B2 (en) | Methods of treatment for septic shock with urine extract | |
WO2015054569A1 (en) | Methods of inhibiting the alternative pathway of complement immune system activation and compositions used therein | |
EP1082131B1 (en) | Immunoregulator | |
CN105641688B (zh) | C1抑制剂在预防缺血-再灌注损伤中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED |
|
AC | Divisional application: reference to earlier application |
Ref document number: 3071219 Country of ref document: EP Kind code of ref document: P |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20191212 |
|
RAX | Requested extension states of the european patent have changed |
Extension state: BA Payment date: 20191212 Extension state: ME Payment date: 20191212 |
|
RBV | Designated contracting states (corrected) |
Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20200214 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40008415 Country of ref document: HK |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: SHIRE VIROPHARMA LLC |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20210601 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
INTC | Intention to grant announced (deleted) | ||
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20220218 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AC | Divisional application: reference to earlier application |
Ref document number: 3071219 Country of ref document: EP Kind code of ref document: P |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1508209 Country of ref document: AT Kind code of ref document: T Effective date: 20220815 Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602014084530 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20220803 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220803 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220803 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221205 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221103 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220803 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220803 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220803 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220803 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220803 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1508209 Country of ref document: AT Kind code of ref document: T Effective date: 20220803 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220803 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221203 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220803 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221104 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220803 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220803 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220803 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220803 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220803 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602014084530 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220803 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220803 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220803 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220803 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
26N | No opposition filed |
Effective date: 20230504 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230529 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20221130 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20221130 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20221130 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220803 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20221121 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20221121 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20221130 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20231019 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20231019 Year of fee payment: 10 Ref country code: FR Payment date: 20231019 Year of fee payment: 10 Ref country code: DE Payment date: 20231019 Year of fee payment: 10 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20141121 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220803 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220803 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220803 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220803 |